Drugs / SAMARIUM DOTMP

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07197645 Oct 2025 → Apr 2027 expected bone neoplasm Telix Pharmaceuticals (Innovations) Pty Limited Recruiting No outcome recorded
Phase 1 NCT03612466 Aug 2022 → Jan 2023 bone neoplasm, osteosarcoma Albert Einstein College of Medicine Withdrawn No outcome recorded
Phase 1 NCT06008483 Apr 2022 → Apr 2024 bone cancer, metastatic malignant neoplasm QSAM Therapeutics, Inc. Unknown No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as SAMARIUM DOTMP ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172
Known as 153SmDOTMP “A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain” NCT07197645
4

“This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP” NCT06008483

NCT07197645

NCT03612466

NCT06008483

Known as CycloSam “This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP” NCT06008483
Known as DOTMP SM-153 ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172
Known as Samarium-153-DOTMP “153-Sm-DOTMP (Samarium-153-DOTMP)” NCT06008483
Known as Sm-153-dotmp ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172
Known as TLX090-Tx “A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain” NCT07197645
Modality Other / unclassified “novel radiopharmaceutical agent” NCT03612466
Route Other “when injected” NCT06008483